Literature DB >> 10401552

Non-NMDA glutamate receptors modulate capsaicin induced c-fos expression within trigeminal nucleus caudalis.

D D Mitsikostas1, M Sanchez del Rio, C Waeber, Z Huang, F M Cutrer, M A Moskowitz.   

Abstract

1. We examined the effects of the alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)/kainate receptor antagonists 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX) and 1,2,3,4-tetrahydro-6-nitro-2,3-dioxo-benzol[f]quinoxaline-7-sulpho namide (NBQX), the kainate receptor antagonists gamma-(R-)-glutamylaminomethanesulphonic acid (GAMS) and 6,7,8,9-tetrahydro-5-nitro-1H-benz[g]indole-2,3-dione-3-oxime (NS-102), and the group III metabotropic glutamate receptor (mGluR) agonist 2-amino-4-phosphono-S-butanoic acid (L-AP4) on c-fos-like immunoreactivity (c-fos LI) in trigeminal caudalis (Sp5C), lateral reticular (LRt), medullary reticular (Md) and solitary tract (Sol) nuclei, after intracisternal injection of capsaicin in urethane anaesthetized Sprague-Dawley rats. 2. Few c-fos labelled cells were observed within Sp5C in capsaicin-vehicle treated animals. The number of positive c-fos cells increased by 17 fold after intracisternal capsaicin (5 nmol) administration. 3. Pretreatment with CNQX (0.02, 0.1, 0.6, 3 and 15 mg kg-1) or NBQX (0.01, 0.1 and 1 mg kg-1), administered intraperitoneally 15 min before capsaicin, significantly reduced labelled cells within Sp5C by a maximum of 45 and 34%, respectively. The number of c-fox LI cells within LRt, Md and Sol was not affected. Pretreatment with L-AP4 (1, 3 and 10 mg kg-1) decreased the number of Sp5C c-fos LI cells by a maximum of 30%, whereas GAMS (1 and 10 mg kg-1) and NS-102 (1 and 5 mg kg-1) did not show any significant effect. 4. These results suggest that blockade of AMPA receptors, but not kainate receptors, or the activation of group III mGluRs, decrease the response of Sp5C neurons to trigeminovascular activation. Thus, in addition to NMDA receptors, mGluRs and AMPA receptors may modulate cephalic pain and may provide a potential therapeutic target for antimigraine drugs.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10401552      PMCID: PMC1566054          DOI: 10.1038/sj.bjp.0702584

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  70 in total

1.  Pharmacology and regional distribution of the binding of 6-[3H]nitro-7-sulphamoylbenzo[f]-quinoxaline-2,3-dione to rat brain.

Authors:  K K Dev; V Petersen; T Honoré; J M Henley
Journal:  J Neurochem       Date:  1996-12       Impact factor: 5.372

2.  Sumatriptan can inhibit trigeminal afferents by an exclusively neural mechanism.

Authors:  K L Hoskin; H Kaube; P J Goadsby
Journal:  Brain       Date:  1996-10       Impact factor: 13.501

3.  Immunoelectron microscopic study of substance P-containing fibers in feline cerebral arteries.

Authors:  L Y Liu-Chen; T M Liszczak; J C King; M A Moskowitz
Journal:  Brain Res       Date:  1986-03-26       Impact factor: 3.252

4.  Electron microscopy of immunoreactivity patterns for glutamate and gamma-aminobutyric acid in synaptic glomeruli of the feline spinal trigeminal nucleus (Subnucleus Caudalis).

Authors:  B Iliakis; N L Anderson; P S Irish; M A Henry; L E Westrum
Journal:  J Comp Neurol       Date:  1996-03-11       Impact factor: 3.215

5.  Immunohistochemical localization of a metabotropic glutamate receptor, mGluR7, in ganglion neurons of the rat; with special reference to the presence in glutamatergic ganglion neurons.

Authors:  J L Li; H Ohishi; T Kaneko; R Shigemoto; A Neki; S Nakanishi; N Mizuno
Journal:  Neurosci Lett       Date:  1996-02-02       Impact factor: 3.046

6.  [3H]-L-2-amino-4-phosphonobutyrate labels a metabotropic glutamate receptor, mGluR4a.

Authors:  L Eriksen; C Thomsen
Journal:  Br J Pharmacol       Date:  1995-12       Impact factor: 8.739

7.  The NMDA receptor antagonist MK-801 reduces Fos-like immunoreactivity in central trigeminal neurons and blocks select endocrine and autonomic responses to corneal stimulation in the rat.

Authors:  David A Bereiter; Dominique F Bereiter; Charles B Hathaway
Journal:  Pain       Date:  1996-01       Impact factor: 6.961

8.  Inhibition of trigeminal neurons by intravenous administration of the serotonin (5HT)1B/D receptor agonist zolmitriptan (311C90): are brain stem sites therapeutic target in migraine?

Authors:  P J Goadsby; K L Hoskin
Journal:  Pain       Date:  1996-10       Impact factor: 6.961

9.  Excitatory amino release within spinal trigeminal nucleus after mustard oil injection into the temporomandibular joint region of the rat.

Authors:  D A Bereiter; A P Benetti
Journal:  Pain       Date:  1996-10       Impact factor: 6.961

10.  N-methyl-D-aspartate and non-N-methyl-D-aspartate receptor antagonism reduces Fos-like immunoreactivity in central trigeminal neurons after corneal stimulation in the rat.

Authors:  D A Bereiter; D F Bereiter
Journal:  Neuroscience       Date:  1996-07       Impact factor: 3.590

View more
  22 in total

1.  GABA receptors modulate trigeminovascular nociceptive neurotransmission in the trigeminocervical complex.

Authors:  R J Storer; S Akerman; P J Goadsby
Journal:  Br J Pharmacol       Date:  2001-10       Impact factor: 8.739

2.  Effects of ionotropic glutamate receptor antagonists on rat dural artery diameter in an intravital microscopy model.

Authors:  K Y Chan; S Gupta; R de Vries; A H J Danser; C M Villalón; E Muñoz-Islas; A Maassenvandenbrink
Journal:  Br J Pharmacol       Date:  2010-07       Impact factor: 8.739

Review 3.  Kynurenines and headache.

Authors:  Arpád Párdutz; Annamária Fejes; Zsuzsanna Bohár; Lilla Tar; József Toldi; László Vécsei
Journal:  J Neural Transm (Vienna)       Date:  2011-06-04       Impact factor: 3.575

4.  Pre-treatment with new kynurenic acid amide dose-dependently prevents the nitroglycerine-induced neuronal activation and sensitization in cervical part of trigemino-cervical complex.

Authors:  Annamária Fejes-Szabó; Zsuzsanna Bohár; Enikő Vámos; Gábor Nagy-Grócz; Lilla Tar; Gábor Veres; Dénes Zádori; Márton Szentirmai; János Tajti; István Szatmári; Ferenc Fülöp; József Toldi; Árpád Párdutz; László Vécsei
Journal:  J Neural Transm (Vienna)       Date:  2014-01-03       Impact factor: 3.575

Review 5.  Glutamate and Its Receptors as Therapeutic Targets for Migraine.

Authors:  Jan Hoffmann; Andrew Charles
Journal:  Neurotherapeutics       Date:  2018-04       Impact factor: 7.620

6.  The effects of the TRPV1 receptor antagonist SB-705498 on trigeminovascular sensitisation and neurotransmission.

Authors:  G A Lambert; J B Davis; J M Appleby; B A Chizh; K L Hoskin; A S Zagami
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2009-08-19       Impact factor: 3.000

7.  Estradiol replacement modifies c-fos expression at the spinomedullary junction evoked by temporomandibular joint stimulation in ovariectomized female rats.

Authors:  K Okamoto; D F Bereiter; R Thompson; A Tashiro; D A Bereiter
Journal:  Neuroscience       Date:  2008-08-08       Impact factor: 3.590

Review 8.  Current and prospective pharmacological targets in relation to antimigraine action.

Authors:  Suneet Mehrotra; Saurabh Gupta; Kayi Y Chan; Carlos M Villalón; David Centurión; Pramod R Saxena; Antoinette MaassenVanDenBrink
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-07-15       Impact factor: 3.000

Review 9.  Glutamate receptor antagonists in the management of migraine.

Authors:  Kayi Chan; Antoinette MaassenVanDenBrink
Journal:  Drugs       Date:  2014-07       Impact factor: 9.546

10.  Calcitonin gene-related peptide (CGRP) modulates nociceptive trigeminovascular transmission in the cat.

Authors:  Robin James Storer; Simon Akerman; Peter J Goadsby
Journal:  Br J Pharmacol       Date:  2004-07-05       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.